Prohost Letter #414 GIANTS & DWARFS - We believe it’s a useful idea bringing The Week …

As expected by those who welcome good news from publicly-traded firms, the Food and Drug Administration …

Two game changing news has come together on October 16, 2017, both indicating that  Exelixis (EXEL) …

Yes, indeed, the FDA Advisory Committee Unanimously Recommends Approval of Investigational LUXTURNA™ (voretigene neparvovec) for Patients …

–The Agreement Covers the Development of Investigational Plasma Kallikrein Inhibitors for Diabetic Macular Edema (DME) – Upfront Fee …

On November 2, 2017 Mannkind (MNKD) announced that the FDA has approved an update to its …

Realizing the dream of approval of a small biotech’s lead drug would usually lead a small …

AstraZeneca’s (AZN) checkpoint PD-L1 inhibitor Imfinzi and NewLink Genetics’ (NLNK) IDO inhibitor indoximod will be combined …

The Week in Review #5 ALNYLAM (ALNY) and Sanofi Genzyme, the specialty care global business unit …

Prohost Letter #413 FROM BIOTECH TO BIOPHARMA - New research, new findings, new discoveries of trustworthy and …